First Patient Enrolled in Investigator-Sponsored Phase 1/2 Trial of Antigenics' Oncophage Cancer Vaccine in Glioma
Antigenics Inc. announced that the Brain Tumor Research Center at the University of California, San Francisco, has initiated a Phase 1/2 clinical trial of Oncophage® (vitespen; formerly HSPPC-96), Antigenics' investigational patient-specific cancer vaccine, as a treatment for patients with recurrent glioma. The primary goal of the investigator-sponsored study is to establish the feasibility, safety and preliminary efficacy of Oncophage vaccination in glioma patients. Glioma is a cancer affecting the central nervous system (brain and spinal cord) that begins in the connective tissue that surrounds and supports nerve cells. Malignant glioma is currently a fatal disease.
Derived from each individual's tumor, Oncophage, which is an investigational therapy, contains the 'antigenic fingerprint' of the patient's particular cancer, and in theory is designed to reprogram the body's immune system to target only cancer cells bearing this fingerprint. Oncophage is intended to leave healthy tissue unaffected and limit the debilitating side effects typically associated with traditional cancer treatments such as chemotherapy and radiation therapy. Oncophage has been granted fast track and orphan drug designations from the US Food and Drug Administration (FDA) in both metastatic melanoma and renal cell carcinoma.
The Phase 1/2 trial is designed to enroll about 60 patients with primary or recurrent high-grade glioma. Patients will undergo surgery to remove their tumors, which are then used to manufacture their patient-specific vaccines. According to the protocol, primary patients will receive vaccine upon recurrence, whereas patients with recurrent disease will be treated after surgery.
The trial is designed to sequentially evaluate the safety of three dosing regimens of Oncophage. The objectives of the two-phase trial are to determine the safety of Oncophage in this patient population; clinical response to therapy, including time to disease progression and overall survival rate; and immune response to therapy. The trial will be supported through a grant from the American Brain Tumor Association and the National Cancer Institute Special Programs of Research Excellence. About Brain and Spinal Cord Tumors
Other news from the department science
